The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 6 , Pages 1644-1651 , June 2010

Persistent plasminogen activator inhibitor 1 gene expression in cardiac transplant recipients with idiopathic dilated cardiomyopathy

  • Romana Schäfer, PhD

      Affiliations

    • Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria
    • ,
  • Katharina Krenn, MD

      Affiliations

    • Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria
    • Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
    • ,
  • Matthias Gmeiner, MD

      Affiliations

    • Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria
    • Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria
    • ,
  • Dietmar Abraham, PhD

      Affiliations

    • Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria
    • ,
  • Seyedhossein Aharinejad, MD, PhD

      Affiliations

    • Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria
    • Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria
    • Corresponding Author InformationAddress for reprints: Seyedhossein Aharinejad, MD, PhD, Department of Cardiothoracic Surgery, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.

Received 16 July 2008 ,Revised 19 August 2009 ,Accepted 8 September 2009.

References 

  1. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 2002;16:147–154
  2. Chorostowska-Wynimko J, Skrzypczak-Jankun E, Jankun J. Plasminogen activator inhibitor type-1 controls the process of the in vitro sprout formation. J Physiol Pharmacol. 2004;55(suppl 3):49–56
  3. Demyanets S, Kaun C, Rychli K, Rega G, Pfaffenberger S, Afonyushkin T, et al. The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI3 kinase and ERK 1/2 dependent pathways. Am J Physiol Heart Circ Physiol. 2007;293:H1962–H1968
  4. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res. 2004;95:637–644
  5. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol. 2005;166:15–25
  6. Croucher DR, Saunders DN, Lobov S, Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer. 2008;8:535–545
  7. Kathiresan S, Gona P, Larson MG, Vita JA, Mitchell GF, Tofler GH, et al. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation. 2006;113:938–945
  8. Schäfer R, Abraham D, Paulus P, Blumer R, Grimm M, Wojta J, et al. Impaired VE-cadherin/beta-catenin expression mediates endothelial cell degeneration in dilated cardiomyopathy. Circulation. 2003;108:1585–1591
  9. Aharinejad S, Krenn K, Paulus P, Schäfer R, Zuckermann A, Grimm M, et al. Differential role of TGF-beta1/bFGF and ET-1 in graft fibrosis in heart failure patients. Am J Transplant. 2005;5:2185–2192
  10. Funauchi M, Shimadsu H, Tamaki T, Yamagata T, Nozaki Y, Sugiyama M, et al. Role of endothelial damage in the pathogenesis of interstitial pneumonitis in patients with polymoysitis an dermatomyositis. J Rheumatol. 2006;33:903–906
  11. Benza RL, Cavender MA, Barchue J, Tallaj JA, Bourge RC, Kirklin JK, et al. Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern. J Heart Lung Transplant. 2007;26:494–497
  12. Warshofsky MK, Wasserman HS, Wang W, Teng P, Sciacca R, Apfelbaum M, et al. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients. Am J Cardiol. 1997;80:145–149
  13. Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different strains. Br J Pharmacol. 2002;135:284–292
  14. Zins K, Abraham D, Sioud M, Aharinejad S. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res. 2007;67:1038–1045
  15. Benza RL, Anderson PG, Lyle K, Barchue J, de Oliveira AL, Cavender MA, et al. Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease. J Heart Lung Transplant. 2003;22:515–518
  16. Benza RL, Cavender MA, Barchue J, Tallaj JA, Bourge RC, Kirklin JK, et al. Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern. J Heart Lung Transplant. 2007;26:494–497
  17. Sartori TM, Maurizio PG, Sara P, Ugolino L, Annalisa A, Panagiotis T, et al. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. J Heart Lung Transplant. 1999;18:693–700
  18. Wilkins-Port CE, Higgins CE, Freytag J, Higgins SP, Carlson JA, Higgins PJ. PAI-1 is a critical upstream regulator of the THF-b/EGF-induced invasive Phenotype in mutant p53 human cutaneous squamous cell carcinoma. J Biomed Biotechnol. 2007;2007:85208
  19. Abraham D, Hofbauer R, Schäfer R, Blumer R, Paulus P, Miksovsky A, et al. Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ Res. 2000;87:644–647

 Supported by grant no. P22371-B19 of the Austrian Science Foundation to S. Aharinejad.

 Disclosures: None.

PII: S0022-5223(10)00047-4

doi: 10.1016/j.jtcvs.2009.09.071

The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 6 , Pages 1644-1651 , June 2010

Article Tools

* Image Usage & Resolution